Drug intelligence / Profile preview

capecitabine + toripalimab

Development stage: Unknown
Lead developer: Junshi Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Capecitabine + toripalimab is a combination therapy consisting of capecitabine, an oral fluoropyrimidine chemotherapy agent, and toripalimab, a humanized immunoglobulin G4 monoclonal antibody against PD-1 (programmed cell death protein 1). This combination has shown promising antitumor activity and manageable safety profile in clinical trials for nasopharyngeal carcinoma, particularly for residual disease after definitive treatment and as maintenance therapy after first-line treatment.

Brand names: LoqtorziTuoyiXeloda
Other names: JS001 + capecitabinetoripalimab + capecitabine

Targets

PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)

Beyond the preview

Go deeper on capecitabine + toripalimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on capecitabine + toripalimab.

Explore the full profile